# Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

> **NCT00621673** · PHASE4 · TERMINATED · sponsor: **Bayer** · enrollment: 1 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Kogenate (BAY 14-2222)

## Key facts

- **NCT ID:** NCT00621673
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621673, "Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00621673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*